Searchable abstracts of presentations at key conferences in endocrinology

ea0037ep1159 | Clinical Cases–Pituitary/Adrenal | ECE2015

Sellar plasmacytoma masquerading as pituitary macroadenoma – a case report

Rajic Antonela Sabati , Skerget Matevz , Gomezelj Sarah

A 49-year-old male presenting with acute onset strabismus on left lateral gaze was admitted to the Endocrinology Department. The CT scan showed a 35×40×25 mm tumor mass, presumed to be a pituitary macroadenoma, in the sellar region which extended into the sphenoidal sinus, clivus, posterior ethmoidal cells, petrous part of the temporal bone and towards the nasopharynx. A MR scan of the head also revealed that the mass displaced the anterior pituitary gland and the in...

ea0041ep273 | Clinical case reports - Pituitary/Adrenal | ECE2016

Addison’s disease caused by adrenal gland tuberculosis

Rajic Antonela Sabati , Merkac Maja Ivartnik , Svetina Petra

Addison’s disease (primary adrenal cortical failure) is the lack of glucocorticoids due to disease of the adrenal gland. At 1855, when Addison described it tuberculosis (TB) was the main etiology. May be we are coming to that time. TB is an infectious disease caused by Mycobacterium tuberculosis. The most commonly (third of the patients) affects the lungs, as well as the other organs. Symptoms of the disease are non specific and are deteriorating slowly, so the d...

ea0056p99 | Clinical case reports - Pituitary/Adrenal | ECE2018

Addison’s disease due to bilateral adrenal hemorrhage as the first presentation of diffuse large B-cell lymphoma

Rajic Antonela Sabati , Kogoj Tina Krokter , Kocjan Tomaz

A 49-year-old previously healthy man suddenly felt severe and constant bilateral lumbar pain. Clinical examination was otherwise normal. Abdominal CT scan showed subacute hematomas in both adrenal glands (sized 10 cm right and 8 cm left). Basic laboratory tests were completely normal. Hormonal testing excluded pheochromocytoma and other hormonally active adrenal tumors. Adrenal insufficiency was confirmed by short Synacthen test and substitution therapy with hydrocortisone was...

ea0056p102 | Clinical case reports - Pituitary/Adrenal | ECE2018

Addison’s disease due to bilateral adrenal hemorrhage as the firstpresentation of diffuse large B-cell lymphoma

Rajic Antonela Sabati , Kogoj Tina Krokter , Kocjan Tomaz

A 49-year-old previously healthy man suddenly felt severe and constant bilateral lumbar pain. Clinical examination was otherwise normal. Abdominal CT scan showed subacute hematomas in both adrenal glands (sized 10 cm right and 8 cm left). Basic laboratory tests were completely normal. Hormonal testing excluded pheochromocytoma and other hormonally active adrenal tumors. Adrenal insufficiency was confirmed by short Synacthen test and substitution therapy with hydrocortisone was...

ea0049ep36 | Adrenal cortex (to include Cushing's) | ECE2017

Transformation from Addison’s disease to adrenocortical carcinoma presented as Cushing’s syndrome with androgenisation

Rajic Antonela Sabati , Resman Kristina Groti , Kocjan Tomaž , Pfeifer Marija

We present a female patient 56 years old, who was treated at the endocrinology department from the year 2006. The diagnosis of Addison’s disease was established and she was properly treated. At the same time primary hypothyroidism was diagnosed, also started treating it properly. She was regularly controlled more often at the first time, than yearly at outpatient clinic. In September 2015 she was in menopause. A few months before she noticed oedematous legs and arms and d...

ea0037ep97 | Steroids, development and paediatric endocrinology | ECE2015

Unusual presentation of the apparent mineralocorticoid excess, triggered by mild Cushing's disease in an adult

Zavratnik Andrej , Zavrsnik Matej , Ksela Urska , Homsak Evgenija , Rajic Antonela Sabati , Gruson Damien , Pfeifer Marija

Introduction: The syndrome of apparent mineralocorticoid excess (AME), a genetic disorder, resembles findings similar to those in primary aldosteronism, but aldosterone levels are low. AME is due to deficiency in the 11-beta-hydroxysteroid-dehydrogenase-enzyme-type-2 isoform (11-beta-HSD2), which normally converts cortisol to cortisone to prevent its mineralocorticoid activity at the aldosterone-sensitive sites. The deficiency in 11-beta-HSD2 leads to marked elevation in net m...

ea0056p188 | Bone ' Osteoporosis | ECE2018

Bone mineral density decline following denosumab discontinuation might not be attenuated with previous bisphosphonate therapy

Japelj Miha , Vidmar Gaj , Rajic Antonela Sabati , Pfeifer Marija , Kocjan Tomaz

Objective: Limited data suggest that the rebound increase in bone resorption and rapid bone mineral density (BMD) decline following sudden interruption of denosumab therapy can be avoided in patients previously treated with bisphosphonates. We aimed to compare BMD changes in osteoporotic patients after denosumab discontinuation regarding their previous bisphosphonate (BP) therapy.Material and methods: There were 14 women (age 69 years, BMI 23.1 kg/m...

ea0049oc10.4 | Bone & Calcium Homeostasis | ECE2017

The effect of denosumab or bisphosphonates in women with severe postmenopausal osteoporosis after completion of teriparatide treatment

Kocjan Tomaz , Rajic Antonela Sabati , Sever Mojca Jensterle , Vidmar Gaj , Ostanek Barbara , Marc Janja , Orehek Nina , Pfeifer Marija

The ideal antiresorptive agent to preserve or further increase bone mineral density (BMD) following teriparatide treatment is not known. We aimed to compare BMD changes after one year of therapy with denosumab or bisphosphonates in osteoporotic patients who had completed treatment with teriparatide. We retrospectively analyzed 140 women (age 74 years, 26 years from menopause, BMI 27 kg/m2 on average) with severe postmenopausal osteoporosis who had been treated betwe...

ea0049gp39 | Bone & Calcium Homeostasis 1 | ECE2017

Association of changes in serum urate level and bone mineral density during treatment with teriparatide: a retrospective observational study

Kocjan Tomaz , Vidmar Gaj , Rajic Antonela Sabati , Jensterle Sever Mojca , Pfeifer Marija , Marc Janja , Orehek Nina , Ostanek Barbara

Serum urate level has recently been associated with increased bone mineral density (BMD). Teriparatide, an osteoanabolic medication for osteoporosis, is associated with increased incidence of hyperuricemia. Hence, we hypothesized that changes in serum urate are associated with changes in BMD and procollagen type 1 N-terminal propeptide (P1NP) during treatment with teriparatide.We collected data from 151 women (mean age 72 years, mean BMI 26.6 kg/m2<...